Abstract
Objective
Because recombinant human activated protein C (rhAPC) reduces NO production during sepsis, it could improve the vascular tone. We tested whether rhAPC reduces the dose of norepinephrine required to maintain mean arterial pressure (MAP) in septic shock patients.
Design and setting
Retrospective study in intensive care unit of two university hospitals.
Patients
Twenty-two septic shock patients with at least two organ failures were retrospectively investigated for MAP and the required dose of norepinephrine before and 24 h after rhAPC administration. A control group of 22 septic shock patients with at least two organ failures who did not receive rhAPC was matched on age, SAPS II, MAP, and norepinephrine dose at the time of the theoretical start of rhAPC.
Measurements and results
The MAP remained stable and similar in the two groups (86±16 vs. 89±9 mmHg at 24 h). The required dose of norepinephrine increased in the control group (+38%, from −41% to +38%) but decreased in the treated group (−33%, from −74% to +11%).
Conclusions
rhAPC rapidly improved the vascular tone in septic shock patients as assessed by a decrease in the norepinephrine dose required to maintain arterial pressure.
This is a preview of subscription content, log in via an institution to check access.
References
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Sessler CN, Shepherd W (2002) New concepts in sepsis. Curr Opin Crit Care 8:465–472
Vallet B (2003) Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care 7:130–138
Szabo C, Mitchell JA, Thiemermann C, Vane JR (1993) Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 108:786–792
Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, Okabe K (2001) Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104:1171–1175
Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF (2004) Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21:222–229
Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B (2003) Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102:2093–2098
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL (2003) Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894–903
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, 3rd, Bernard GR (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834–840
Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG (2005) Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280:17286–17293
Bourgoin A, Leone M, Delmas A, Garnier F, Albanese J, Martin C (2005) Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 33:780–786
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Monnet, X., Lamia, B., Anguel, N. et al. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med 31, 1573–1576 (2005). https://doi.org/10.1007/s00134-005-2792-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-005-2792-0